{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:27:12Z","timestamp":1791354432691,"version":"4.3.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-21262-5","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T13:53:38Z","timestamp":1761573218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Combinatorial QM and MD in silico design of natural product-based DHFR inhibitors"],"prefix":"10.1038","volume":"15","author":[{"given":"Sepideh","family":"Kalhor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin Mohammad","family":"Shapouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Fattahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"21262_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/emmm.200900040","volume":"1","author":"SA Martin","year":"2009","unstructured":"Martin, S. A. et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol. Med. 1, 323\u2013337. https:\/\/doi.org\/10.1002\/emmm.200900040 (2009).","journal-title":"EMBO Mol. Med."},{"key":"21262_CR2","doi-asserted-by":"crossref","unstructured":"Avenda\u00f1o, C. and Men\u00e9ndez, J.C. Antimetabolites that interfere with nucleic acid biosynthesis.\u00a0Medicinal Chemistry of Anticancer Drugs, 41\u201353 (2015).","DOI":"10.1016\/B978-0-444-62649-3.00002-8"},{"key":"21262_CR3","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3390\/molecules24061140","volume":"24","author":"MV Raimondi","year":"2019","unstructured":"Raimondi, M. V. et al. DHFR inhibitors: Reading the past for discovering novel anticancer agents. Molecules 24, 1140. https:\/\/doi.org\/10.3390\/molecules24061140 (2019).","journal-title":"Molecules"},{"key":"21262_CR4","unstructured":"xPharm: The Comprehensive Pharmacology Reference,2007, pp 1\u20136."},{"key":"21262_CR5","doi-asserted-by":"publisher","unstructured":"Srinivasan*, B., Tonddast-Navaei, S., Roy$, A., Zhou, H. & Skolnick, J. Chemical space of Escherichia coli dihydrofolate reductase inhibitors: New approaches for discovering novel drugs for old bugs. Med. Res. Rev. 39, 684\u2013705. https:\/\/doi.org\/10.1002\/med.21538 (2019).","DOI":"10.1002\/med.21538"},{"key":"21262_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1634\/theoncologist.1-1-68","volume":"1","author":"CH Takimoto","year":"1996","unstructured":"Takimoto, C. H. New antifolates: pharmacology and clinical applications. J. Oncol. 1, 68\u201381. https:\/\/doi.org\/10.1634\/theoncologist.1-1-68 (1996).","journal-title":"J. Oncol."},{"key":"21262_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s11912-003-0098-3","volume":"5","author":"WT Purcell","year":"2003","unstructured":"Purcell, W. T. & Ettinger, D. S. Novel antifolate drugs. Oncol. Rep. 5, 114\u2013125. https:\/\/doi.org\/10.1007\/s11912-003-0098-3 (2003).","journal-title":"Oncol. Rep."},{"key":"21262_CR8","doi-asserted-by":"crossref","unstructured":"Jackman, A.L. Ed. Antifolate Drugs in Cancer Therapy. Springer Science & Business Media (1999).","DOI":"10.1007\/978-1-59259-725-3"},{"key":"21262_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejmech.2017.01.033","volume":"128","author":"M Wang","year":"2017","unstructured":"Wang, M. et al. Synthesis and antiproliferative activity of a series of novel 6-substituted pyrido [3, 2-d] pyrimidines as potential nonclassical lipophilic antifolates targeting dihydrofolate reductase. Eur. J. Med. Chem. 128, 88\u201397. https:\/\/doi.org\/10.1016\/j.ejmech.2017.01.033 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"21262_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1021\/jm00106a001","volume":"34","author":"EM Berman","year":"1991","unstructured":"Berman, E. M. & Werbel, L. M. The renewed potential for folate antagonists in contemporary cancer chemotherapy. J. Med. Chem. 34, 479\u2013485. https:\/\/doi.org\/10.1021\/jm00106a001 (1991).","journal-title":"J. Med. Chem."},{"key":"21262_CR11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jsb.2009.01.001","volume":"166","author":"BC Bennett","year":"2009","unstructured":"Bennett, B. C., Wan, Q., Ahmad, M. F., Langan, P. & Dealwis, C. G. X-ray structure of the ternary MTX\u00b7 NADPH complex of the anthrax dihydrofolate reductase: A pharmacophore for dual-site inhibitor design. J. Struct. Biol. 166, 162\u2013171. https:\/\/doi.org\/10.1016\/j.jsb.2009.01.001 (2009).","journal-title":"J. Struct. Biol."},{"key":"21262_CR12","doi-asserted-by":"publisher","first-page":"22970","DOI":"10.1074\/jbc.C115.671123","volume":"290","author":"D Rushworth","year":"2015","unstructured":"Rushworth, D., Mathews, A., Alpert, A. & Cooper, L. J. Dihydrofolate reductase and thymidylate synthase transgenes resistant to methotrexate interact to permit novel transgene regulation. J. Biol. Chem. 290, 22970\u201322976. https:\/\/doi.org\/10.1074\/jbc.C115.671123 (2015).","journal-title":"J. Biol. Chem."},{"key":"21262_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/CMR.S10043","volume":"2","author":"N Hagner","year":"2010","unstructured":"Hagner, N. & Joerger, M. Cancer chemotherapy: Targeting folic acid synthesis. Cancer Manag. Res. 2, 293\u2013301. https:\/\/doi.org\/10.2147\/CMR.S10043 (2010).","journal-title":"Cancer Manag. Res."},{"key":"21262_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1056\/NEJM198602203140803","volume":"314","author":"WE Evans","year":"1986","unstructured":"Evans, W. E. et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. N. Engl. J. Med. 314, 471\u2013477. https:\/\/doi.org\/10.1056\/NEJM198602203140803 (1986).","journal-title":"N. Engl. J. Med."},{"key":"21262_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-019-0982-4","volume":"19","author":"H Toyonaga","year":"2019","unstructured":"Toyonaga, H., Fukushima, M., Shimeno, N. & Inokuma, T. Methotrexate-associated lymphoproliferative disorder in the stomach and duodenum: a case report. BMC Gastroenterol. 19, 1\u20136. https:\/\/doi.org\/10.1186\/s12876-019-0982-4 (2019).","journal-title":"BMC Gastroenterol."},{"key":"21262_CR16","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/pbc.20314","volume":"44","author":"S Zelcer","year":"2005","unstructured":"Zelcer, S. et al. Methotrexate levels and outcome in osteosarcoma. Pediatr. Blood. Cancer. 44, 638\u2013642. https:\/\/doi.org\/10.1002\/pbc.20314 (2005).","journal-title":"Pediatr. Blood. Cancer."},{"key":"21262_CR17","first-page":"125","volume":"65","author":"GP Canellos","year":"1981","unstructured":"Canellos, G. P., Skarin, A. T., Rosenthal, D. S., Moloney, W. C. & Frei, E. 3rd. Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin\u2019s lymphoma of unfavorable histology. Cancer. Treat. Rep. 65, 125\u2013129 (1981).","journal-title":"Cancer. Treat. Rep."},{"key":"21262_CR18","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1039\/D0MD00051E","volume":"11","author":"V Yang","year":"2020","unstructured":"Yang, V. et al. Breast cancer: insights in disease and influence of drug methotrexate. RSC Med. Chem. 11, 646\u2013664. https:\/\/doi.org\/10.1039\/D0MD00051E (2020).","journal-title":"RSC Med. Chem."},{"key":"21262_CR19","doi-asserted-by":"crossref","unstructured":"Natale, R.B., Yagoda, A., Watson, R.C., Whitmore, W.F., Blumenreich, M., Braun Jr, D.W. Methotrexate: An active drug in bladder cancer.\u00a0Cancer,\u00a047, 1246\u20131250. https:\/\/doi.org\/10.1002\/1097-0142(19810315)47:6<1246::AID-CNCR2820470603>3.0.CO;2-G (1981).","DOI":"10.1002\/1097-0142(19810315)47:6<1246::AID-CNCR2820470603>3.0.CO;2-G"},{"key":"21262_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/00000441-195102000-00009","volume":"221","author":"R Gubner","year":"1951","unstructured":"Gubner, R., August, S. & Ginsberg, V. Therapeutic suppression of tissue reactivity. 2. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am. J. Med. Sci. 221, 176\u2013182. https:\/\/doi.org\/10.1097\/00000441-195102000-00009 (1951).","journal-title":"Am. J. Med. Sci."},{"key":"21262_CR21","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/art.20278","volume":"50","author":"JM Kremer","year":"2004","unstructured":"Kremer, J. M. Toward a better understanding of methotrexate. Arthritis Rheumatol. 50, 1370\u20131382 (2004).","journal-title":"Arthritis Rheumatol."},{"key":"21262_CR22","unstructured":"Chabner, B. A. & Longo, D. L. Cancer Chemotherapy and Biotherapy: Principles and Practice. 5th edn (Wolters Kluwer, Lippincott Williams & Wilkins, 2011). ISBN 978-1-60547-431-1, 1-60547-431-2."},{"key":"21262_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.5555\/19471404507","volume":"170","author":"BL Hutchings","year":"1947","unstructured":"Hutchings, B. L. et al. Pteroylaspartic acid, an antagonist for pteroylglutamic acid. J. Biol. Chem. 170, 323\u2013328. https:\/\/doi.org\/10.5555\/19471404507 (1947).","journal-title":"J. Biol. Chem."},{"key":"21262_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/pbc.21764","volume":"52","author":"F Brugnoletti","year":"2009","unstructured":"Brugnoletti, F. et al. Recurrent intrathecal methotrexate induced neurotoxicity in an adolescent with acute lymphoblastic leukemia: Serial clinical and radiologic findings. Pediatr. Blood. Cancer. 52, 293\u2013295. https:\/\/doi.org\/10.1002\/pbc.21764 (2009).","journal-title":"Pediatr. Blood. Cancer."},{"key":"21262_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/mpo.2950020313","volume":"2","author":"WH Isacoff","year":"1976","unstructured":"Isacoff, W. H. et al. High dose methotrexate therapy of solid tumors: Observations relating to clinical toxicity. Med. Pediatr. Oncol. 2, 319\u2013325. https:\/\/doi.org\/10.1002\/mpo.2950020313 (1976).","journal-title":"Med. Pediatr. Oncol."},{"key":"21262_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/rheumatology\/keh512","volume":"44","author":"AJ Kinder","year":"2005","unstructured":"Kinder, A. J. et al. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology 44, 61\u201366. https:\/\/doi.org\/10.1093\/rheumatology\/keh512 (2005).","journal-title":"Rheumatology"},{"key":"21262_CR27","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/0190-9622(91)70199-C","volume":"25","author":"EA Olsen","year":"1991","unstructured":"Olsen, E. A. The pharmacology of methotrexate. J. Am. Acad. Dermatol. 25, 306\u2013318. https:\/\/doi.org\/10.1016\/0190-9622(91)70199-C (1991).","journal-title":"J. Am. Acad. Dermatol."},{"key":"21262_CR28","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","volume":"11","author":"BC Widemann","year":"2006","unstructured":"Widemann, B. C. & Adamson, P. C. Understanding and managing methotrexate nephrotoxicity. J. Oncol. 11, 694\u2013703. https:\/\/doi.org\/10.1634\/theoncologist.11-6-694 (2006).","journal-title":"J. Oncol."},{"key":"21262_CR29","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.drudis.2017.02.001","volume":"22","author":"NG Bednarska","year":"2017","unstructured":"Bednarska, N. G., Wren, B. W. & Willcocks, S. J. The importance of the glycosylation of antimicrobial peptides: natural and synthetic approaches. Drug Discov. Today 22, 919\u2013926. https:\/\/doi.org\/10.1016\/j.drudis.2017.02.001 (2017).","journal-title":"Drug Discov. Today"},{"key":"21262_CR30","doi-asserted-by":"publisher","first-page":"5859","DOI":"10.1021\/jm300418d","volume":"55","author":"P Varamini","year":"2012","unstructured":"Varamini, P. et al. Synthesis and biological evaluation of an orally active glycosylated endomorphin-1. J. Med. Chem. 55, 5859\u20135867. https:\/\/doi.org\/10.1021\/jm300418d (2012).","journal-title":"J. Med. Chem."},{"key":"21262_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/med.20039","volume":"25","author":"R Polt","year":"2005","unstructured":"Polt, R., Dhanasekaran, M. & Keyari, C. M. Glycosylated neuropeptides: A new vista for neuropsychopharmacology?. Med. Res. Rev. 25, 557\u2013585. https:\/\/doi.org\/10.1002\/med.20039 (2005).","journal-title":"Med. Res. Rev."},{"key":"21262_CR32","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1021\/bi981195e","volume":"38","author":"HH Ho","year":"1999","unstructured":"Ho, H. H., Gilbert, M. T., Nussenzveig, D. R. & Gershengorn, M. C. Glycosylation is important for binding to human calcitonin receptors. Biochemistry 38, 1866\u20131872. https:\/\/doi.org\/10.1021\/bi981195e (1999).","journal-title":"Biochemistry"},{"key":"21262_CR33","doi-asserted-by":"publisher","first-page":"183264","DOI":"10.1016\/j.bbamem.2020.183264","volume":"1862","author":"S Grissenberger","year":"2020","unstructured":"Grissenberger, S., Riedl, S., Rinner, B., Leber, R. & Zweytick, D. Design of human lactoferricin derived antitumor peptides-activity and specificity against malignant melanoma in 2D and 3D model studies. Biochim Biophys Acta Biomembr 1862, 183264. https:\/\/doi.org\/10.1016\/j.bbamem.2020.183264 (2020).","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"21262_CR34","doi-asserted-by":"publisher","unstructured":"Jeswani, G. and Paul, S.D. Chapter 15\u2013recent advances in the delivery of chemotherapeutic agents. In Nano- and Microscale Drug Delivery Systems (Grumezescu AM, ed); https:\/\/doi.org\/10.1016\/B978-0-323-52727-9.00015-7 (2017).","DOI":"10.1016\/B978-0-323-52727-9.00015-7"},{"key":"21262_CR35","unstructured":"Shao, Y., Fusti-Molnar, L., Jung, Y., Kussmann, J., Ochsenfeld, C., Brown, S. T., ... & DiStasio Jr, R. A., (Wavefunct. Inc.) (Irvine CA, 2011)."},{"key":"21262_CR36","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461. https:\/\/doi.org\/10.1002\/jcc.21334 (2010).","journal-title":"J. Comput. Chem."},{"key":"21262_CR37","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10822-010-9352-6","volume":"24","author":"D Seeliger","year":"2010","unstructured":"Seeliger, D. & de Groot, B. L. Ligand docking and binding site analysis with PyMOL and Autodock\/Vina. J. Comput. Aided Mol. 24, 417\u2013422. https:\/\/doi.org\/10.1007\/s10822-010-9352-6 (2010).","journal-title":"J. Comput. Aided Mol."},{"key":"21262_CR38","doi-asserted-by":"publisher","first-page":"20079","DOI":"10.1074\/jbc.M109.018010","volume":"284","author":"JP Volpato","year":"2009","unstructured":"Volpato, J. P. et al. Multiple conformers in active site of human dihydrofolate reductase F31R\/Q35E double mutant suggest structural basis for methotrexate resistance. J. Biol. Chem. 284, 20079\u201320089. https:\/\/doi.org\/10.1074\/jbc.M109.018010 (2009).","journal-title":"J. Biol. Chem."},{"key":"21262_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-15976-8_1","author":"S P\u00e1ll","year":"2014","unstructured":"P\u00e1ll, S., Abraham, M. J., Kutzner, C., Hess, B. & Lindahl, E. Tackling exascale software challenges in molecular dynamics simulations with GROMACS. EASC. https:\/\/doi.org\/10.1007\/978-3-319-15976-8_1 (2014).","journal-title":"EASC."},{"key":"21262_CR40","unstructured":"Biovia, D.S. BIOVIA Discovery Studio Client (v16. 1.0. 15350) (Dassault Systems, 2017)."},{"key":"21262_CR41","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/CCO.0b013e328356da72","volume":"24","author":"K Adekola","year":"2012","unstructured":"Adekola, K., Rosen, S. T. & Shanmugam, M. Glucose transporters in cancer metabolism. Curr. Opin. Oncol. 24, 650\u2013654. https:\/\/doi.org\/10.1097\/CCO.0b013e328356da72 (2012).","journal-title":"Curr. Opin. Oncol."},{"key":"21262_CR42","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.3390\/cancers13164184","volume":"13","author":"M Pliszka","year":"2021","unstructured":"Pliszka, M. & Szablewski, L. Glucose transporters as a target for anticancer therapy. Cancers 13, 4184. https:\/\/doi.org\/10.3390\/cancers13164184 (2021).","journal-title":"Cancers"},{"key":"21262_CR43","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.3390\/pharmaceutics13122065","volume":"13","author":"MC Lucana","year":"2021","unstructured":"Lucana, M. C. et al. Protease-resistant peptides for targeting and intracellular delivery of therapeutics. Pharmaceutics 13, 2065. https:\/\/doi.org\/10.3390\/pharmaceutics13122065 (2021).","journal-title":"Pharmaceutics"},{"key":"21262_CR44","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41557-018-0041-8","volume":"10","author":"TJ Wadzinski","year":"2018","unstructured":"Wadzinski, T. J. et al. Rapid phenolic O-glycosylation of small molecules and complex unprotected peptides in aqueous solvent. Nat. Chem. 10, 644\u2013652. https:\/\/doi.org\/10.1038\/s41557-018-0041-8 (2018).","journal-title":"Nat. Chem."},{"key":"21262_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep35615","volume":"6","author":"T Yamamoto","year":"2016","unstructured":"Yamamoto, T., Shikano, K., Nanki, T. & Kawai, S. Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis. Sci. Rep. 6, 1\u20138. https:\/\/doi.org\/10.1038\/srep35615 (2016).","journal-title":"Sci. Rep."},{"key":"21262_CR46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey, W., Dalke, A. & Schulten, K. V. M. D. Visual molecular dynamics. J. Mol. Gr. 14, 33\u201338. https:\/\/doi.org\/10.1016\/0263-7855(96)00018-5 (1996).","journal-title":"J. Mol. Gr."},{"key":"21262_CR47","doi-asserted-by":"publisher","first-page":"1288652","DOI":"10.3389\/fmolb.2023.1288652","volume":"10","author":"S Baammi","year":"2023","unstructured":"Baammi, S., El Allali, A. & Daoud, R. Potent VEGFR-2 inhibitors for resistant breast cancer: a comprehensive 3D-QSAR, ADMET, molecular docking and MMPBSA calculation on triazolopyrazine derivatives. Front. Mol. Biosci. 10, 1288652. https:\/\/doi.org\/10.3389\/fmolb.2023.1288652 (2023).","journal-title":"Front. Mol. Biosci."},{"key":"21262_CR48","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.1080\/07391102.2023.2238314","volume":"42","author":"H Soufi","year":"2024","unstructured":"Soufi, H. et al. Multi-combined QSAR, molecular docking, molecular dynamics simulation, and ADMET of Flavonoid derivatives as potent cholinesterase inhibitors. J. Biomol. Struct. Dyn. 42, 6027\u20136041. https:\/\/doi.org\/10.1080\/07391102.2023.2238314 (2024).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"21262_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-409547-2.12659-9","author":"G Vistoli","year":"2016","unstructured":"Vistoli, G. & Pedretti, A. Molecular Fields to Assess Recognition Forces and Property Spaces\u2606, reference module in chemistry, molecular sciences and chemical engineering. Elsevier https:\/\/doi.org\/10.1016\/B978-0-12-409547-2.12659-9 (2016).","journal-title":"Elsevier"},{"key":"21262_CR50","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris, G. M. et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785\u20132791. https:\/\/doi.org\/10.1002\/jcc.21256 (2009).","journal-title":"J. Comput. Chem."},{"key":"21262_CR51","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1007\/s00044-015-1409-6","volume":"24","author":"M Mansourian","year":"2015","unstructured":"Mansourian, M., Mahnam, K., Madadkar-Sobhani, A., Fassihi, A. & Saghaie, L. Insights into the human A 1 adenosine receptor from molecular dynamics simulation: Structural study in the presence of lipid membrane. Med. Chem. Res. 24, 3645\u20133659. https:\/\/doi.org\/10.1007\/s00044-015-1409-6 (2015).","journal-title":"Med. Chem. Res."},{"key":"21262_CR52","doi-asserted-by":"crossref","unstructured":"Morris, G.M., et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19, 1639\u20131662. https:\/\/doi.org\/10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B (1998).","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B"},{"key":"21262_CR53","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1021\/bi1000855","volume":"49","author":"JA Lemkul","year":"2010","unstructured":"Lemkul, J. A. & Bevan, D. R. Destabilizing Alzheimer\u2019s A\u03b242 protofibrils with morin: mechanistic insights from molecular dynamics simulations. Biochemistry 49, 3935\u20133946. https:\/\/doi.org\/10.1021\/bi1000855 (2010).","journal-title":"Biochemistry"},{"key":"21262_CR54","doi-asserted-by":"publisher","first-page":"6378","DOI":"10.1021\/jp810292n","volume":"113","author":"AV Marenich","year":"2009","unstructured":"Marenich, A. V., Cramer, C. J. & Truhlar, D. G. Universal solvation model based on solute electron density and on a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions. J. Phys. Chem. B. 113, 6378\u20136396. https:\/\/doi.org\/10.1021\/jp810292n (2009).","journal-title":"J. Phys. Chem. B."},{"key":"21262_CR55","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00214-007-0310-x","volume":"120","author":"Y Zhao","year":"2008","unstructured":"Zhao, Y. & Truhlar, D. G. The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: Two new functionals and systematic testing of four M06-class functionals and 12 other functionals. Theor. Chem. Acc. 120, 215\u2013241. https:\/\/doi.org\/10.1007\/s00214-007-0310-x (2008).","journal-title":"Theor. Chem. Acc."},{"key":"21262_CR56","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1021\/acs.jcim.9b00212","volume":"59","author":"MA Nedyalkova","year":"2019","unstructured":"Nedyalkova, M. A., Madurga, S., Tobiszewski, M. & Simeonov, V. Calculating the partition coefficients of organic solvents in octanol\/water and octanol\/air. J. Chem. Inf. Model. 59, 2257\u20132263. https:\/\/doi.org\/10.1021\/acs.jcim.9b00212 (2019).","journal-title":"J. Chem. Inf. Model."},{"key":"21262_CR57","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/01.NAJ.0000390501.84780.e6","volume":"110","author":"M Thompson","year":"2010","unstructured":"Thompson, M. Material safety data sheets. Am. J. Nurs. 110, 12\u201314. https:\/\/doi.org\/10.1097\/01.NAJ.0000390501.84780.e6 (2010).","journal-title":"Am. J. Nurs."},{"key":"21262_CR58","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0378-5173(00)00599-8","volume":"212","author":"MJ Alvarez-Figueroa","year":"2001","unstructured":"Alvarez-Figueroa, M. J., Delgado-Charro, M. B. & Blanco-Mendez, J. Passive and iontophoretic transdermal penetration of methotrexate. Int. J. Pharm. 212, 101\u2013107. https:\/\/doi.org\/10.1016\/S0378-5173(00)00599-8 (2001).","journal-title":"Int. J. Pharm."},{"key":"21262_CR59","unstructured":"Sangster, J. A Databank of Evaluated Octanol-Water Partition Coefficients (LogP) on Microcomputer Diskette. Bulletin for Sangster Research Laboratories. Canadian National Committee for CODATA, Montreal, Quebec, Canada (1994)."},{"key":"21262_CR60","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13321-020-0408-x","volume":"12","author":"N Schaduangrat","year":"2020","unstructured":"Schaduangrat, N. et al. Towards reproducible computational drug discovery. J. Cheminform. 12, 9. https:\/\/doi.org\/10.1186\/s13321-020-0408-x (2020).","journal-title":"J. Cheminform."},{"key":"21262_CR61","doi-asserted-by":"publisher","first-page":"18461","DOI":"10.1038\/s41598-022-22810-z","volume":"12","author":"S Kalhor","year":"2022","unstructured":"Kalhor, S. & Fattahi, A. Design of amino acid- and carbohydrate-based anticancer drugs to inhibit polymerase \u03b7. Sci. Rep. 12, 18461. https:\/\/doi.org\/10.1038\/s41598-022-22810-z (2022).","journal-title":"Sci. Rep."},{"key":"21262_CR62","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673342605241214044429","volume":"32","author":"S Kalhor","year":"2025","unstructured":"Kalhor, S., Nahr, M. N. N. & Fattahi, A. Investigating synergistic strategies: Integrating linear regression, quantum mechanics, and molecular dynamics for the discovery of novel anticancer drugs targeting MTH1 inhibition. Curr. Med. Chem. 32, e09298673342605. https:\/\/doi.org\/10.2174\/0109298673342605241214044429 (2025).","journal-title":"Curr. Med. Chem."},{"key":"21262_CR63","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41598-037367-z","volume":"9","author":"T Galochkina","year":"2019","unstructured":"Galochkina, T. et al. New insights into GluT1 mechanics during glucose transfer. Sci. Rep. 9, 998. https:\/\/doi.org\/10.1038\/s41598-037367-z (2019).","journal-title":"Sci. Rep."},{"key":"21262_CR64","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4103\/jomfp.JOMFP_22_18","volume":"23","author":"S Pragallapati","year":"2019","unstructured":"Pragallapati, S. & Manyam,. Glucose transporter 1 in health and disease. J. Oral Maxillofac. Pathol. 23, 443. https:\/\/doi.org\/10.4103\/jomfp.JOMFP_22_18 (2019).","journal-title":"J. Oral Maxillofac. Pathol."},{"key":"21262_CR65","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.3390\/ijms20133374","volume":"20","author":"A Zambrano","year":"2019","unstructured":"Zambrano, A., Molt, M., Uribe, E. & Salas, M. Glut 1 in cancer cells and the inhibitory action of resveratrol as a potential therapeutic strategy. Int. J. Mol. Sci. 20, 3374. https:\/\/doi.org\/10.3390\/ijms20133374 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"21262_CR66","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41540-022-00229-6","volume":"8","author":"A Bukkuri","year":"2022","unstructured":"Bukkuri, A., Gatenby, R. A. & Brown, J. S. GLUT1 production in cancer cells: A tragedy of the commons. Npj Syst. Biol. Appl. 8, 22. https:\/\/doi.org\/10.1038\/s41540-022-00229-6 (2022).","journal-title":"Npj Syst. Biol. Appl."},{"key":"21262_CR67","doi-asserted-by":"publisher","first-page":"728759","DOI":"10.3389\/fcell.2021.728759","volume":"9","author":"E Shin","year":"2021","unstructured":"Shin, E. & Koo, J. S. Glucose metabolism and glucose transporters in breast cancer. Front. Cell. Dev. Biol. 9, 728759. https:\/\/doi.org\/10.3389\/fcell.2021.728759 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"21262_CR68","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti, M. V. & Locasale, J. W. The Warburg effect: How does it benefit cancer cells?. Trends Biochem. Sci. 41, 211\u2013218. https:\/\/doi.org\/10.1016\/j.tibs.2015.12.001 (2016).","journal-title":"Trends Biochem. Sci."},{"key":"21262_CR69","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/bs.acc.2015.07.003","volume":"72","author":"I Hoseok","year":"2015","unstructured":"Hoseok, I. & Cho, J. Y. Lung cancer biomarkers. Adv. Clin. Chem. 72, 107\u2013170. https:\/\/doi.org\/10.1016\/bs.acc.2015.07.003 (2015).","journal-title":"Adv. Clin. Chem."},{"key":"21262_CR70","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"TM Allen","year":"2013","unstructured":"Allen, T. M. & Cullis, P. R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65, 36\u201348. https:\/\/doi.org\/10.1016\/j.addr.2012.09.037 (2013).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"21262_CR71","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-017-3025-9","volume-title":"Solitons in Molecular Systems 113","author":"AS Davydov","year":"1985","unstructured":"Davydov, A. S. Solitons in Molecular Systems 113 (Reidel, 1985)."},{"key":"21262_CR72","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1063\/1.464397","volume":"98","author":"T Darden","year":"1993","unstructured":"Darden, T., York, D. & Pedersen, L. Particle mesh Ewald: An N\u22c5 log (N) method for Ewald sums in large systems. J. Chem. Phys. 98, 10089\u201310092. https:\/\/doi.org\/10.1063\/1.464397 (1993).","journal-title":"J. Chem. Phys."},{"key":"21262_CR73","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s00894-015-2631-3","volume":"21","author":"U Yadava","year":"2015","unstructured":"Yadava, U., Shukla, B. K., Roychoudhury, M. & Kumar, D. Pyrazolo [3, 4-d] pyrimidines as novel inhibitors of O-acetyl-L-serine sulfhydrylase of Entamoeba histolytica: An in-silico study. J. Mol. Model. 21, 96. https:\/\/doi.org\/10.1007\/s00894-015-2631-3 (2015).","journal-title":"J. Mol. Model."},{"key":"21262_CR74","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1063\/1.448118","volume":"81","author":"HJ Berendsen","year":"1984","unstructured":"Berendsen, H. J., Postma, J. V., van Gunsteren, W. F., DiNola, A. R. H. J. & Haak, J. R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81, 3684\u20133690. https:\/\/doi.org\/10.1063\/1.448118 (1984).","journal-title":"J. Chem. Phys."},{"key":"21262_CR75","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/ci500020m","volume":"54","author":"R Kumari","year":"2014","unstructured":"Kumari, R. & Kumar, R. Open Source Drug Discovery Consortium, & Lynn, A. g_mmpbsa: A GROMACS tool for high-throughput MM-PBSA calculations. J. Chem. Inf. Model. 54, 1951\u20131962. https:\/\/doi.org\/10.1021\/ci500020m (2014).","journal-title":"J. Chem. Inf. Model."},{"key":"21262_CR76","unstructured":"Martin, T. User\u2019s Guide for TEST (Toxicity Estimation Software Tool) \u2011A Program to Estimate Toxicity from Molecular Structure. pdf version. Vol. 4. 63; https:\/\/www.epa.gov\/sites\/default\/files\/2016-05\/documents\/600r16058.pdf (2016)."},{"key":"21262_CR77","unstructured":"US National Library of Medicine. ChemIDplus. [2016 4\/14\/16]. http:\/\/chem.sis.nlm.nih.gov\/chemidplus\/chemidheavy.jsp."},{"key":"21262_CR78","doi-asserted-by":"publisher","first-page":"379","DOI":"10.4103\/ijp.ijp_899_21","volume":"54","author":"A Mishra","year":"2022","unstructured":"Mishra, A., Dewangan, G., Mandal, T. K. & Chkraborty, J. LD50 dose fixation of nanohybrid-layered double hydroxide-methotrexate. Indian J. Pharmacol. 54, 379\u2013380. https:\/\/doi.org\/10.4103\/ijp.ijp_899_21 (2022).","journal-title":"Indian J. Pharmacol."},{"key":"21262_CR79","unstructured":"AAT Bioquest, Inc. (2024, November 9). Quest Database\u2122 Dihydrofolate reductase Inhibitors (IC50, Ki). AAT Bioquest. https:\/\/www.aatbio.com\/data-sets\/dihydrofolate-reductase-inhibitors-ic50-ki."},{"key":"21262_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101531","author":"LN Heppler","year":"2022","unstructured":"Heppler, L. N. et al. The antimicrobial drug pyrimethamine inhibits STAT3 transcriptional activity by targeting the enzyme dihydrofolate reductase. JBC https:\/\/doi.org\/10.1016\/j.jbc.2021.101531 (2022).","journal-title":"JBC"},{"key":"21262_CR81","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1080\/08927022.2022.2030862","volume":"48","author":"S Kalhor","year":"2022","unstructured":"Kalhor, S. & Fattahi, A. In silico design of novel anticancer drugs with amino acid and carbohydrate building blocks to inhibit PIM kinases. Mol. Simul. 48, 526\u2013540. https:\/\/doi.org\/10.1080\/08927022.2022.2030862 (2022).","journal-title":"Mol. Simul."},{"issue":"W1","key":"21262_CR82","doi-asserted-by":"publisher","first-page":"W5","DOI":"10.1093\/nar\/gkab255","volume":"49","author":"G Xiong","year":"2021","unstructured":"Xiong, G. et al. ADMETlab 2.0: An integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 49(W1), W5\u2013W14 (2021).","journal-title":"Nucleic Acids Res."},{"key":"21262_CR83","first-page":"391","volume":"76","author":"T Lynch","year":"2007","unstructured":"Lynch, T. & Price, A. M. Y. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am. Fam. Physician 76, 391\u2013396 (2007).","journal-title":"Am. Fam. Physician"},{"key":"21262_CR84","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3390\/pharmaceutics17050601","volume":"17","author":"D Calemi","year":"2025","unstructured":"Calemi, D. et al. Evaluation of violacein metabolic stability and metabolite identification in human, mouse, and rat liver microsomes. Pharmaceutics 17, 601. https:\/\/doi.org\/10.3390\/pharmaceutics17050601 (2025).","journal-title":"Pharmaceutics"},{"key":"21262_CR85","doi-asserted-by":"publisher","first-page":"172665","DOI":"10.1016\/j.ejphar.2019.172665","volume":"863","author":"M Zhao","year":"2019","unstructured":"Zhao, M. et al. DHFR\/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide. Eur. J. Pharmacol. 863, 172665. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172665 (2019).","journal-title":"Eur. J. Pharmacol."},{"key":"21262_CR86","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1182\/blood.V90.2.578","volume":"90","author":"LH Matherly","year":"1997","unstructured":"Matherly, L. H. et al. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children. Blood J. Am. Soc. Hematol. 90, 578\u2013589. https:\/\/doi.org\/10.1182\/blood.V90.2.578 (1997).","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"21262_CR87","doi-asserted-by":"publisher","first-page":"8405","DOI":"10.3892\/ol.2018.8429","volume":"15","author":"J Organista-Nava","year":"2018","unstructured":"Organista-Nava, J. et al. Overexpression of dihydrofolate reductase is a factor of poor survival in acute lymphoblastic leukemia. Oncol. Lett. 15, 8405\u20138411. https:\/\/doi.org\/10.3892\/ol.2018.8429 (2018).","journal-title":"Oncol. Lett."},{"key":"21262_CR88","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1182\/blood-2008-07-165928","volume":"113","author":"R de Jonge","year":"2009","unstructured":"de Jonge, R. et al. Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood J. Am. Soc. Hematol. 113, 2284\u20132289. https:\/\/doi.org\/10.1182\/blood-2008-07-165928 (2009).","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"21262_CR89","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10555-007-9049-z","volume":"26","author":"YG Assaraf","year":"2007","unstructured":"Assaraf, Y. G. Molecular basis of antifolate resistance. Cancer Metastasis Rev. 26, 153\u2013181. https:\/\/doi.org\/10.1007\/s10555-007-9049-z (2007).","journal-title":"Cancer Metastasis Rev."},{"key":"21262_CR90","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/stem.140005","volume":"14","author":"JR Bertino","year":"1996","unstructured":"Bertino, J. R., G\u00f6ker, E., Gorlick, R., Li, W. W. & Banerjee, D. Resistance mechanisms to methotrexate in tumors. Stem Cells 14, 5\u20139. https:\/\/doi.org\/10.1002\/stem.140005 (1996).","journal-title":"Stem Cells"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21262-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21262-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21262-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:02:37Z","timestamp":1761962557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21262-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["21262"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-21262-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"8 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37462"}}